New quarterly report expected Apr 22, 2026. Report will refresh after results.
P
Penumbra, Inc.
PEN · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
STORM-PE Validates the Thesis; The Stock Already Knows
The market is treating STORM-PE as a catalyst to trade around, but the more important signal is that pulmonologists and hematologists — not interventionalists — are volunteering to rewrite hospital protocols, which means the adoption bottleneck just shifted from physician supply to patient identification, an order-of-magnitude larger funnel. The peripheral vascular opportunity, priced as an incremental add-on to the neuro story, may actually be the main event.
Flowly Score
Apr 16 Close
-16%$331.47
Fair Value
$280.00
52
Averageat $331.47
Business Strength7/10
The consumables model is elegant and the switching costs in neuro are genuinely structural — physicians don't retrain their hands under life-or-death conditions. The VR distraction and the heavy dependence on Indigo as a single franchise within peripheral vascular keep this from a higher score.
Financial Resilience7/10
The Piotroski and Altman scores reflect a business in excellent financial health, and the FCF inflection from incinerator to cash machine in three years is a step-change worth respecting. The Q4 cash drop deserves monitoring, but the operating leverage story is clearly intact.
Growth & Trajectory8/10
STORM-PE is not an incremental data point — it's a randomized controlled trial demonstrating superiority over the decades-old standard of care in a massive indication, and non-interventionalists saying they'll lead protocol updates is the exact adoption signal that unlocks exponential volume. Two platforms, two large underpenetrated markets, one very positive clinical tailwind.
Valuation3/10at $339.61
The stock is priced for the optimistic DCF scenario and then some, with the neutral case implying substantial downside — and a five-year average ROIC near zero means the burden of proof for sustaining the 2025 inflection is high. At nearly seventy times earnings, there is essentially no margin for error in execution or adoption curves.
Risk4/10
The concentrated US revenue base means a single CMS reimbursement decision or a hospital capital budget cycle can move the needle sharply, and the 2025 CapEx surge at nearly four times depreciation is either visionary capacity-building or a significant value drag — the answer won't be clear for two or three years. Thunderbolt's FDA timing adds binary near-term uncertainty on top of a valuation that is already priced for everything going right.
Penumbra has done something genuinely rare: it willed a new standard of care into existence, built the clinical evidence base to defend it, and structured a consumables business that gets paid every time a physician acts on that evidence. The quality of the underlying business is real. The problem is the price, which assumes the optimistic DCF scenario unfolds without friction — sustained near-peak revenue growth, continued margin expansion, and successful Thunderbolt clearance — while offering essentially no cushion if adoption curves disappoint or the CapEx surge proves less productive than management expects. You are paying for perfection in a business that spent most of its history generating returns below its cost of capital. Where this business is heading is more interesting than where it has been. STORM-PE's randomized evidence for intermediate high-risk pulmonary embolism is the kind of data that restructures medical practice over a three-to-five-year window, not a quarter. The detail that non-interventional physicians are enthusiastic is critical — it signals demand creation from the referring physician side, not just supply from trained operators. If PE becomes a volume business the way stroke thrombectomy became a volume business, the Indigo franchise in five years could dwarf the neuro business that built the company's reputation. The single biggest specific risk is the 2025 capital expenditure surge. Nearly four times depreciation is an enormous number for a business at this scale, and the market is currently treating it as growth investment rather than catch-up or remediation spending. If that assumption is wrong — if some portion reflects quality system investment, regulatory compliance, or simply inefficient capacity build — the normalized FCF figure used to anchor the optimistic valuation case is materially overstated, and a multiple compression from current levels would be severe.